| 0.9401 -0.026 (-2.71%) | 04-26 10:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.19 |
1-year : | 1.28 |
| Resists | First : | 1.01 |
Second : | 1.1 |
| Pivot price | 0.97 |
|||
| Supports | First : | 0.88 | Second : | 0.74 |
| MAs | MA(5) : | 0.94 |
MA(20) : | 0.98 |
| MA(100) : | 1.11 |
MA(250) : | 1.8 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 27.7 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 6.4 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BNOX ] has closed above bottom band by 25.5%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 93 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.91 - 0.91 | 0.91 - 0.92 |
| Close: | 0.96 - 0.97 | 0.97 - 0.97 |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Thu, 21 Mar 2024
Bionomics reports promising PTSD treatment trial results By Investing.com - Investing.com
Wed, 20 Mar 2024
Bionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023) - Simply Wall St
Thu, 22 Feb 2024
Bionomics to Present at the 2024 BIO CEO & Investor Conference - GlobeNewswire
Mon, 22 Jan 2024
Bionomics Provides a Review of 2023 and of 2024 Plans - Yahoo Finance
Wed, 04 Oct 2023
Steve Cohen Bets Again On Biopharma With Purchase Of 119M+ Bionomics Shares - The Dales Report
Fri, 29 Sep 2023
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 1.28e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 86 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.572e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 466.2 % |
| Return on Equity (ttm) | -35.2 % |
| Qtrly Rev. Growth | 661980 % |
| Gross Profit (p.s.) | -5.40217e+006 |
| Sales Per Share | 3.27174e+006 |
| EBITDA (p.s.) | -1.08315e+007 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 258390 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|